# Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL

> **NCT07677878** · PHASE1 · RECRUITING · sponsor: **Liping Dou** · enrollment: 60 (estimated)

## Conditions studied

- ALL (Acute B-Lymphoblastic Leukemia)

## Interventions

- **DRUG:** Blinatumomab Injection
- **OTHER:** Donor Lymphocyte Infusion (DLI)

## Key facts

- **NCT ID:** NCT07677878
- **Lead sponsor:** Liping Dou
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-01
- **Primary completion:** 2028-11-30
- **Final completion:** 2028-12-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07677878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07677878, "Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07677878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*